fatty liver
DESCRIPTION
Fatty Liver. Shahin Merat, M.D. Associate Professor of Medicine Digestive Disease Research Center, Tehran University of Medical Sciences, 8 th International Congress of Endocrine Disorders Tehran, Oct 2009. Fatty Liver (aka steatosis). Any amount of fat in liver histology - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/1.jpg)
FATTY LIVERShahin Merat, M.D.Associate Professor of MedicineDigestive Disease Research Center, Tehran University of Medical Sciences,8th International Congress of Endocrine DisordersTehran, Oct 2009
![Page 2: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/2.jpg)
FATTY LIVER (AKA STEATOSIS) Any amount of fat in liver histology
Mirovesicular or macrovesicular With or without inflammation With or without fibrosis Associated with other disease or not Alcohol related or not
Alcoholic fatty liver Non alcoholic fatty liver (NAFL)
2
![Page 3: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/3.jpg)
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Defined as:
Deposition of fat droplets in hepatocytes AND the absence of significant alcohol intake
Generally defined as less than 20gr ethanol per week NAFLD is a range of conditions from near
normal liver to cirrhosis
3
![Page 4: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/4.jpg)
OTHER TERMS Simple non-alcoholic fatty liver disease
(NAFLD) Only deposition of fat in liver No inflammation or fibrosis
Non-Alcoholic Steatohepatitis (NASH) NAFLD with inflammation (lobular or portal),
hepatocyte ballooning, or fibrosis Absence of serologic evidence of infection with
hepatitis B or hepatitis C, …
4
![Page 5: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/5.jpg)
NAFLD—SPECTRUM OF DISEASE
Steatosis
Steatohepatitis (NASH)
NASH with Fibrosis
Cirrhosis5
NAFLD
![Page 6: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/6.jpg)
NAFLD, SIMPLE STEATOSIS Fatty Liver
Only deposition of fat in liver No inflammation No fibrosis Not believed to progress to cirrhosis Up to 25 % of some populations!
6
![Page 7: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/7.jpg)
NAFLD—STEATOSIS
7
Source: Ibdah 2003
![Page 8: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/8.jpg)
NAFLD—NASH (WITHOUT FIBROSIS)
8
Source: Ibdah 2003
![Page 9: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/9.jpg)
NAFLD—NASH (WITH FIBROSIS)
Source: Ibdah 2003
9
![Page 10: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/10.jpg)
10
![Page 11: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/11.jpg)
MULTIPLE HIT THEORY
11/22
Normal Liver
Fatty Liver
Steatohepatitis
Cirrhosis
Hit 1: ? Insulin resistance, endotoxins, …
Fat accumulationHit 2: ? Oxidative stress, …
Inflammation
Hit 3: ? Oxidative stress, …
FibrosisMay loose fat
![Page 12: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/12.jpg)
NAFLD—HISTOLOGICAL SPECTRUM
Macrovesicular Steatosis
Lobular Inflammation
Fibrosis
Cirrhosis
Tim
e Pr
ogre
ssio
n
![Page 13: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/13.jpg)
IMPACT Liver-related death rate:
General population: 9.5/100,000 NASH: 11% !
Liver-related deaths were the second most common cause of death in NAFL
13
![Page 14: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/14.jpg)
NATURAL HISTORY In various follow-up studies (4-18
years) Improved: 0-4%No change: 50-60%Progession: 40-45%
Fibrosis: 27% Cirrhosis: 19%
Much better than alcoholic hepatitisApproximately 38-50% progress to
cirrhosis over seven years14
![Page 15: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/15.jpg)
NAFLD—CLINICAL PREDICTORS
Patients at risk to develop NASH with fibrosis:
A. Age > 45
B. Obesity (BMI > 31-32)
C. Diabetes
D. AST/ALT > 1
15
![Page 16: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/16.jpg)
SURVIVALNASH (Hepatology 2001)
5-year all-cause survival: 67%10-year all-cause survival: 59%
Alcoholic hepatitis5-year survival: 38%10-year survival: 15%
Hepatitis C with compensated cirrhosis 384 cases (Gastroenterology 1997)5-year survival: 91%10-year survival: 79%
16
![Page 17: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/17.jpg)
HEPATITIS C (AS A COMPARISON) 222 cases of Hepatitis C and 377 controls
after 25 years of follow-up: (Hepatology 2001) All cause mortality in HCV: 67% In controls: 65% (not significant)
917 women with acute HCV due to contaminated anti-D immune globulin (Hepatology 2000) After 20 yrs: 0.4% cirrhosis
Shiraz liver transplant cases (n=207) (2005): Cryptogenic cirrhosis: 23% (most common cause) Hepatitis B: 17% Hepatitis C: 2%
17
![Page 18: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/18.jpg)
![Page 19: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/19.jpg)
NASH, EPIDEMIOLOGY (WORLD) The most common cause of elevated enzyme
levels among asymptomatic patients Only 10% of NAFLD have NASH Among patients who have had liver biopsies,
NASH is seen in approximately 7-9% in Western countries
19
![Page 20: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/20.jpg)
EPIDEMIOLOGY There are many indications that a large
number of patients labeled as cryptogenic cirrhosis have been cases of NASH who have lost indications of NASH.
There is evidence that the increased rate of cirrhosis and liver-related death in many conditions such as diabetics and malabsorbtion states (eg celiac disease) is due to NASH
20
![Page 21: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/21.jpg)
NASH, PREVALENCE IN IRANNASH is considered as the hepatic
manifestation of the metabolic syndrome (syndrome X).
In a large scale study on 10,368 subjects in Tehran, the prevalence of the metabolic syndrome was found to be 30.1% (Azizi et al.)
This study did not look to the liver tests or its ultrasonographic appearance, but it can be considered a good estimation of the at-risk population in Iran.
21
![Page 22: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/22.jpg)
NASH, PREVALENCE IN IRAN An autopsy series on 895 consecutive deaths
from non-medical causes (Sotoudehmanesh et al) 283 (31.6%) had steatosis 19 (2.1%) had steatohepatitis 6.7% of cases of steatosis had steatohepatitis
Non had alcohol consumption or diabetes Post-mortem changes ?
22
![Page 23: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/23.jpg)
NASH, PREVALENCE IN IRAN 1959 blood donors
Subjects with abnormal liver enzymes were invided
Further studies performed Viral studies Ultrasonography
2.35% NASH
23
![Page 24: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/24.jpg)
NASH, PREVALENCE IN IRAN Only 2.2% of these cases had a BMI of less
than 25 Limitations:
The population studied was 75.1% male. No histologic confirmation Cases studied were among volunteer blood donors
obese subjects are more likely to donate blood high risk subjects are screened out.
Nevertheless, this is currently the only published study addressing the prevalence of NASH in Iran’s general population.
Another study on 6,000 randomly selected subjects from the general population is on the way
24
![Page 25: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/25.jpg)
NASH, DIAGNOSIS Poorly studied
Many doctors do not even believe in NASH! Benign compared to other hepatitis
One of the most common ways by which NAFLD comes to medical attention is its incidental report during abdominal ultrasonography.
Unfortunately some ultrasonographists don’t believe in NAFLD too!
25
![Page 26: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/26.jpg)
NASH, DIAGNOSIS Most patients are asymptomatic. Hepatomegaly is the most common physical
finding. ALT / AST > 1, usually not so high Ultrasound will demonstrate a fatty or “bright
liver.” In CT, the liver is darker than the spleen Liver biopsy is required
26
![Page 27: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/27.jpg)
DIAGNOSIS, ULTRASONOGRAPHY Unfortunately many radiologists in Iran do
not report mild steatosis Technically unsuitable equipment ? Simple negligence ? They don’t believe in it!
27
![Page 28: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/28.jpg)
DIAGNOSIS, ULTRASONOGRAPHY Increased echogenecity of the liver
parenchyma, white liver Not the same as coarse echogenicity which is
a sign of fibrosis Can be staged to grade I, II, and III according
to vascular blurring or visibility of the diaphragm
28
![Page 29: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/29.jpg)
![Page 30: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/30.jpg)
![Page 31: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/31.jpg)
31/54
![Page 32: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/32.jpg)
DIAGNOSIS, CT The liver and spleen usually have equal, or
near-equal, density In hepatic steatosis the liver is hypodense
when compared to the spleen You may see liver angiogram even without
contrast injection
32
![Page 33: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/33.jpg)
33
![Page 34: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/34.jpg)
SUMMARY (1/2) It appears that about 30% of the adult
population in Iran is at risk for NAFLDThe overweight, obese, and diabetic is
more prone. About 10% of these subjects, almost 2-
3% of the general adult population, already have NASH.
In may be roughly estimated that 10% of NASH cases will progress to cirrhosis. 34
![Page 35: Fatty Liver](https://reader036.vdocuments.net/reader036/viewer/2022062812/56816334550346895dd3be95/html5/thumbnails/35.jpg)
SUMMARY (2/2)The prevalence of NASH (2-3%) is
comparable to the prevalence of hepatitis B, and much larger than the prevalence of hepatitis C
Since hepatitis B is being vaccinated for, we will be seeing less of this disease in the future
But obesity is on the rise. (as is hepatitis C)
It can be concluded that in the near future, NASH and hepatitis C will be the major liver diseases we will be facing in Iran 35